Nicotinamide N‐methyltransferase inhibition improves limb function in experimental peripheral artery disease
Physiological Reports · 2025
DOI: 10.14814/phy2.70615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2025. Verfasst von Gengfu Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Physiology and Kinesiology, The University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Nicotinamide N-Methyltransferase, Muscle, Skeletal, Ischemia. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association (AHA), NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI).
Abstract (Originalsprache)
Peripheral artery disease (PAD) impairs limb perfusion, walking ability, and increases the risk of amputation. Although current therapies reduce cardiovascular events, few interventions improve skeletal muscle function in PAD. Nicotinamide adenine dinucleotide (NAD + ) metabolism is disrupted in PAD. Thus, it was hypothesized that inhibition of nicotinamide N‐methyltransferase (NNMT), an enzyme that diverts precursors from the NAD + salvage pathway, would improve ischemic limb function. We analyzed NAD + pathway expression in gastrocnemius muscle from patients with and without PAD using RNA sequencing and proteomics datasets. Single‐cell RNA sequencing data were used to assess NNMT expression in muscle stem cells (MuSCs) from BALB/cJ and C57BL/6J mice following hindlimb ischemia (HLI). Male BALB/cJ mice ( n = 24) were randomized to either placebo or a NNMT inhibitor (NNMTi) delivered 3 h prior to HLI and daily thereafter. Functional assessments included laser Doppler perfusion imaging, muscle contractility, and a 6‐min limb function test. Histological analyses were used to assess myofiber area and capillary density. NNMT mRNA and protein levels were significantly elevated in skeletal muscle from patients with PAD and were persistently elevated in MuSCs from BALB/cJ mice after HLI. NNMTi treatment did not affect limb perfusion recovery or capillary density but trended toward reduced necrosis severity ( p = 0.08). Muscle mass and myofiber size were unchanged by treatment; however, NNMTi significantly improved muscle strength ( p < 0.0001), power ( p = 0.0305), and total work ( p = 0.0367) in ischemic limbs compared to placebo. Inhibition of NNMT enhanced ischemic muscle strength and performance in a preclinical model of PAD independent of changes in perfusion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Physiology and Kinesiology, The University of Florida, Gainesville, Florida, USA.
- Center for Exercise Science, The University of Florida, Gainesville, Florida, USA.
- Myology Institute, The University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Terence E Ryan
Förderung
- American Heart Association (AHA)
- NHLBI NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- National Heart, Lung, and Blood Institute
Zitieren
APA
Dong, G., Choi, J., Li, Y., Muller, D. C., Li, Z., Luo, Y. E., & Ryan, T. E. (2025). Nicotinamide N‐methyltransferase inhibition improves limb function in experimental peripheral artery disease. Physiological Reports. https://doi.org/10.14814/phy2.70615
Vancouver
Dong G, Choi J, Li Y, Muller DC, Li Z, Luo YE, et al. Nicotinamide N‐methyltransferase inhibition improves limb function in experimental peripheral artery disease. Physiological Reports. 2025. doi:10.14814/phy2.70615
BibTeX
@article{Dong2025,
author = {Dong, Gengfu and Choi, Jaewon and Li, Yufen and Muller, Diana C and Li, Zhuoxin and Luo, Yangyi E and Ryan, Terence E},
title = {Nicotinamide N‐methyltransferase inhibition improves limb function in experimental peripheral artery disease},
journal = {Physiological Reports},
year = {2025},
doi = {10.14814/phy2.70615}
}
EUVIMED